Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Debt to Equity (2020 - 2025)

Maravai Lifesciences Holdings has reported Debt to Equity over the past 6 years, most recently at $0.78 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.78 for Q4 2025, up 52.69% from a year ago — trailing twelve months through Dec 2025 was $0.78 (up 52.69% YoY), and the annual figure for FY2025 was $0.78, up 52.69%.
  • Debt to Equity for Q4 2025 was $0.78 at Maravai Lifesciences Holdings, down from $1.19 in the prior quarter.
  • Over the last five years, Debt to Equity for MRVI hit a ceiling of $1.79 in Q1 2021 and a floor of $0.51 in Q4 2024.
  • Median Debt to Equity over the past 5 years was $0.77 (2023), compared with a mean of $0.9.
  • Biggest five-year swings in Debt to Equity: plummeted 60.28% in 2021 and later soared 52.69% in 2025.
  • Maravai Lifesciences Holdings' Debt to Equity stood at $1.37 in 2021, then crashed by 57.54% to $0.58 in 2022, then grew by 13.89% to $0.66 in 2023, then dropped by 22.74% to $0.51 in 2024, then soared by 52.69% to $0.78 in 2025.
  • The last three reported values for Debt to Equity were $0.78 (Q4 2025), $1.19 (Q3 2025), and $0.63 (Q2 2025) per Business Quant data.